Gabriele Varano

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.

The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.

Journal: Blood cancer discovery

Published: December 23, 2025

RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.

RAG1/2 expression in IGH-switched follicular lymphoma associated with transformation to high-grade B-cell lymphoma.

Journal: Leukemia

Published: December 09, 2025

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction.

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction.

Journal: Hematological oncology

Published: December 06, 2025

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction.

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction.

Journal: Hematological oncology

Published: December 06, 2025

B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.

B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.

Journal: Blood cancer discovery

Published: March 19, 2025

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.

Journal: The Journal of clinical investigation

Published: September 30, 2024

Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.

Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma.

Journal: Research square

Published: April 02, 2024

Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.

Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.

Journal: Cancer research

Published: February 01, 2023

Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies.

Optical tissue clearing associated with 3D imaging: application in preclinical and clinical studies.

Journal: Histochemistry and cell biology

Published: January 28, 2022

MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship.

MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship.

Journal: Cells

Published: June 21, 2021

The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma.

The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma.

Journal: Genes

Published: April 02, 2021

The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies.

The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies.

Journal: Frontiers in oncology

Published: February 27, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026